Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer

P. Benedetti-Panici, S. Greggi, G. Scambia, M. G. Salerno, G. Baiocchi, G. Laurelli, G. Menichella, L. Pierelli, M. L. Foddai, R. Serafini, B. Bizzi, S. Mancuso

Research output: Contribution to journalArticle

Abstract

20 patients with stage III-IV ovarian cancer were submitted to induction chemotherapy (ICT) (40 mg/m2 cisplatin, days 1-4; 1.5 g/m2 cyclophosphamide, day 4; every 4 weeks for 2 cycles) followed by intensified CT (100 mg/m2 cisplatin, day 1; 650 mg/m2 etoposide, day 2; 1.8 g/m2 carboplatin by 24 h infusion, day 3). Haematological support consisted of autologous peripheral stem cells (APSC) and bone marrow (ABM) transplant (T) in 16 and 4 patients, respectively. All patients were evaluable for toxicity and 19 for pathological response (PR), one patient dying of systemic mycosis after ABMT. Severe (grade 3-4) non-haematological toxic effects were gastrointestinal (100%), neurological (10%) and hepatic (10%). PR was observed in 84% of patients (complete response 37%, partial response with microscopic residual disease 26%, partial response with macroscopic residual disease 21%). Five year overall survival was 60% and progression-free survival was 51% with 9 patients still disease-free (DFS). APSCT significantly reduced the duration of aplasia compared with ABMT, and toxicity was acceptable in those patients undergoing APSCT. The prolonged DFS in patients showing PCR suggests that this new approach may have a therapeutic impact.

Original languageEnglish
Pages (from-to)1987-1992
Number of pages6
JournalEuropean Journal of Cancer
Volume31
Issue number12
DOIs
Publication statusPublished - 1995

Keywords

  • autologous peripheral stem cell transplantation
  • high-dose chemotherapy
  • ovarian carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Benedetti-Panici, P., Greggi, S., Scambia, G., Salerno, M. G., Baiocchi, G., Laurelli, G., Menichella, G., Pierelli, L., Foddai, M. L., Serafini, R., Bizzi, B., & Mancuso, S. (1995). Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. European Journal of Cancer, 31(12), 1987-1992. https://doi.org/10.1016/0959-8049(95)00337-1